Immunome Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.9M | $9.0M | $14.0M | — | — |
| Research and development | $177.3M | $129.5M | $23.1M | $23.3M | $14.1M |
| Operating expenses | $231.1M | $314.8M | $123.5M | $36.9M | $25.2M |
| Operating income | -$224.1M | -$305.8M | -$109.5M | -$36.9M | -$25.2M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$212.4M | -$293.0M | -$106.8M | -$36.9M | -$24.7M |
| Balance Sheet | |||||
| Cash and equivalents | $653.5M | $143.4M | $98.7M | $20.3M | $49.2M |
| Current assets | $660.8M | $221.3M | $144.7M | $22.6M | $56.6M |
| Total assets | $683.2M | $240.2M | $148.5M | $24.0M | $57.9M |
| Current liabilities | $45.0M | $54.3M | $21.8M | $7.3M | $9.7M |
| Total liabilities | $48.8M | $59.1M | $28.7M | $7.4M | $9.7M |
| Stockholders' equity | $634.3M | $181.2M | $119.9M | $16.7M | $48.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$190.9M | -$110.8M | -$7.6M | -$28.7M | -$18.2M |
| Depreciation and amortization | $2.5M | $1.6M | $457,000 | $422,000 | $755,000 |
| Stock-based compensation | $25.7M | $15.7M | $6.2M | $5.3M | $3.4M |
| Capital expenditure | $9.7M | $7.2M | $831,000 | $248,000 | $79,000 |
| Free cash flow | -$200.6M | -$118.0M | -$8.4M | -$28.9M | -$18.3M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 113.3M · Free float 83.0%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.